Cyted Health Secures $44 Million in Series B Financing to Accelerate US Expansion

Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company, today announces a first close of $44 million in its Series B financing round to accelerate its ongoing US expansion.

The round was led by EQT Life Sciences, investing through its EQT Health Economics strategy, and co-led by Advent Life Sciences and British Business Bank with continued support from existing investors Morningside and BGF.  

The financing will be used to accelerate the commercial expansion of Cyted’s diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests. Cyted’s existing platform consists of EndoSign®, an FDA 510(k)-cleared device enabling minimally invasive collection of esophageal cells, and advanced biomarker molecular testing for the detection of esophageal conditions.

Cyted’s technology has already demonstrated significant success across the UK’s National HealthService, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications proving unmatched patient acceptability and real-world clinical impact. Esophageal cancer is considered one of the deadliest cancers globally, with a survival rate of only 20%.

“This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier,”said Marcel Gehrung, CEO and Co-founder of Cyted Health. “This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.”

Bruno Holthof, Partner at EQT Life Sciences, commented: “Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide.Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we’re delighted to add the company to our portfolio.”

“Cyted has demonstrated a rare combination of clinical innovation, patient-centered delivery, and commercial execution with an impressive foundation in the UK. We’re proud to support its next phase of growth,” said Kaasim Mahmood, General Partner at Advent Life Sciences.

Carmine Circelli, Director, Life Sciences at British Business Bank, added: “Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally.”

Science Minister Lord Vallance said: "I am pleased to see the British Business Bank back Cyted - a company whose growth demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities with the potential to improve people's lives. Life sciences form a critical part of this Government's ambitions for both the economy and healthcare - and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success.”

Founded by leading experts at the University of Cambridge, Cyted is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions.

Cyted’s Series B financing round follows the recent launch of Cyted's DETECT-ME clinical validation study, which has been enrolling patients across multiple sites in the US since March 2025. This study will validate clinical performance of Cyted’s newest assays and molecular tests for the detection of esophageal conditions using EndoSign®.